Neovacs -- Paris, October 22, 2009 -- Neovacs, a biotechnology company developing proprietary immunotherapeutics for autoimmune and chronic diseases, today released a summary of preclinical results achieved with its Interferon alpha (IFNa) Kinoid immunotherapy for lupus, as presented in a poster at the ACR/ARHP 2009 Annual Scientific Meeting (October 17th-21st in Philadelphia).
